CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a central organ for devastating rare diseases, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will participate in two upcoming conferences:
- Milken Institute Global Conference 2016
Panel: Biotech: Bull Market or Bubble?
Wednesday, May 4th, 2016 at 10:00 a.m. Pacific Time
The Beverly Hilton Hotel, Beverly Hills, CA
- Piper Jaffray GenomeRx Symposium
Panel: Systemic Delivery of Gene Therapy: Hemophilia & Beyond
Tuesday, May 17, 2016 at 9:50 a.m. Eastern Time
The InterContinental New York Barclay Hotel, New York, NY
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency and GSDIa, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.